Do you have Eosinophilic Esophagitis? Consider joining a study of a medication.

Now Recruiting Study Participants Qualified participants: Receive study-related care at no cost from a local doctor

No need for health insurance See If You Qualify First Name Last Name Email Address Phone Study Details We are participating in a national study of a medication called Dupilumab in patients with Eosinophilic Esophagitis (EoE).

Eosinophilic Esophagitis or Eoe is an allergic inflammatory disease that damages the lining of the esophagus leading to difficulty swallowing.

Dupilumab is a medication made by Regeneron Pharmaceuticals.

The safety and efficacy of Dupilumab for use in patients with Eosinophilic Esophagitis is being evaluated in this study.

Dupixent is FDA approved for the treatment of moderate to severe atopic dermatitis, moderate to severe asthma, and chronic rhinosinusitis with nasal polyposis.

It is not FDA approved for the treatment of Eosinophilic Esophagitis. See If You Qualify First Name Last Name Email Address Phone